KLI

Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19

Metadata Downloads
Abstract
Background/Aims: The rapidity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific memory B or T cell response in vaccinated individuals is important for our understanding of immunopathogenesis of coronavirus disease 2019 (COVID-19). We therefore compared the timing of adequate immune responses between the first and booster doses of COVID-19 vaccines in infection-naïve healthcare workers.

Methods: We enrolled healthcare workers who received two doses of either the BNT162b2 vaccine or the ChAdOx1 vaccine, all of whom received the BNT162b2 vaccine as the booster (the third) dose. Spike 1 (S1)-immunoglobulin G (IgG) antibodies and interferon gamma producing T cell responses were measured at 0, 7, 14, and 21 days after the first dose, and at 0 and between 2 to 7 days after the booster dose.

Results: After the first-dose vaccination, the S1-IgG antibody responses were elicited within 14 days in the BNT162b2 group and within 21 days in the ChAdOx1 group. After the booster dose, the S1-IgG antibody responses were elicited within 5 days in both groups. The SARS-CoV-2-specific T cell responses appeared at 7 days after the first dose and at 4 days after the booster dose.

Conclusions: SARS-CoV-2-specific immune responses by memory B cells and T cells may be expected to appear around 4 to 5 days after the booster dose.
Author(s)
Ji Yeun KimJi-Soo KwonHye Hee ChaSo Yun LimSeongman BaeSung-Han Kim
Issued Date
2022
Type
Article
Keyword
Antibody formationPrimarySecondaryCOVID-19 vaccines
DOI
10.3904/kjim.2022.173
URI
https://oak.ulsan.ac.kr/handle/2021.oak/14338
Publisher
Korean Journal of Internal Medicine
Language
한국어
ISSN
1226-3303
Citation Volume
37
Citation Number
6
Citation Start Page
1234
Citation End Page
1240
Appears in Collections:
Medicine > Nursing
공개 및 라이선스
  • 공개 구분공개
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.